Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers Webinar Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers CertaraMarch 9, 2026
Navigate GxP Compliance in the Cloud with Confidence Guide Navigate GxP Compliance in the Cloud with Confidence Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…CertaraMarch 6, 2026
Understanding and Calculating Steady State Pharmacokinetics BlogKnowledge Base Understanding and Calculating Steady State Pharmacokinetics Steady state pharmacokinetics can seem abstract and confusing. Read this blog to gain a better…CertaraMarch 5, 2026
Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer Publication Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…Danielle PillsburyMarch 4, 2026
ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success Blog ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…CertaraMarch 3, 2026
Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes Blog Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…CertaraFebruary 27, 2026
Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit) On-Demand Webinar Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit) This webinar introduces the Phoenix IVIVC Toolkit, showing how to perform BE analysis and build…CertaraFebruary 27, 2026
Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Webinar Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Danielle PillsburyFebruary 23, 2026
Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs) Webinar Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs) CertaraFebruary 23, 2026